Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence

다국어 초록 (Multilingual Abstract)

Coronaviruses have caused serious Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19) outbreaks, and only remdesivir has been recently indicated for the treatment of COVID-19. In the line of therapeutic options for SARS and MERS, this study aims to summarize the current clinical evidence of treatment options for COVID-19. In general, the combination of antibiotics, ribavirin, and corticosteroids was considered as a standard treatment for patients with SARS. The addition of this conventional treatment with lopinavir/ritonavir, interferon, and convalescent plasma showed potential clinical improvement. For patients with MERS, ribavirin, lopinavir/ritonavir, interferon, and convalescent plasma were continuously recommended. However, a high-dose of corticosteroid was suggested for severe cases only. The use of lopinavir/ritonavir and convalescent plasma was commonly reported. There was limited evidence for the effect of corticosteroids, other antiviral drugs like ribavirin, and favipiravir. Monoclonal antibody of tocilizumab and antimalarial agents of chloroquine and hydroxychloroquine were also introduced. Among antibiotics for infection therapy, azithromycin was suggested. In conclusion, this study showed the up-to-date evidence of treatment options for COVID-19 that is helpful for the therapy selection and the development of further guidelines and recommendations. Updates of on-going clinical trials and observational studies may confirm the current findings.

참고문헌 (Reference)

1 World Health Organization (WHO), "WHO Director-General's opening remarks at the media briefing on COVID-19"

2 Jin Y, "Virology, epidemiology, pathogenesis, and control of COVID-19" 12 : 3722-, 2020

3 Sarma P, "Virological and clinical cure in Covid-19 patients treated with hydroxychloroquine : a systematic review and meta-analysis" 92 : 776-785, 2020

4 Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong" 24 : 44-46, 2005

5 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea" 대한의학회 35 (35): 1-8, 2020

6 Hung IF, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial" 395 : 1695-1704, 2020

7 Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir/ritonavir : a multicentre retrospective matched cohort study" 9 : 399-406, 2003

8 Shen C, "Treatment of 5 critically ill patients with COVID-19 with convalescent plasma" 323 : 1582-1589, 2020

9 Momattin H, "Therapeutic options for Middle East respiratory syndrome coronavirus(MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy" 17 : e792-e798, 2013

10 Liu T, "The potential role of IL-6 in monitoring severe case of coronavirus disease 2019"

11 Epidemiology Working Group for NCIP Epidemic Response, "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China" 41 : 145-151, 2020

12 Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology : a systematic review and exploratory meta-analysis" 211 : 80-90, 2015

13 Han W, "The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019" 92 : 461-463, 2020

14 Lim J, "The author's response : Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea : the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia Monitored by quantitative RT-PCR" 35 : e79-, 2020

15 Alhazzani W, "Surviving sepsis campaign : guidelines on the management of critically ill adults with coronavirus disease 2019(COVID-19)" 46 : 854-887, 2020

16 World Health Organization (WHO), "Statement on the first meeting of the International Health Regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV)"

17 Sung JJ, "Severe acute respiratory syndrome : report of treatment and outcome after a major outbreak" 59 : 414-420, 2004

18 Tsui PT, "Severe acute respiratory syndrome : clinical outcome and prognostic correlates" 9 : 1064-1069, 2003

19 Chan MH, "Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome" 255 : 512-518, 2004

20 Tsang K, "SARS: pharmacotherapy" 8 (8): S25-S30, 2003

21 Stockman LJ, "SARS : systematic review of treatment effects" 3 : e343-, 2006

22 Chu CM, "Role of lopinavir/ritonavir in the treatment of SARS : initial virological and clinical findings" 59 : 252-256, 2004

23 Hu L, "Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China" ciaa539-, 2020

24 Arabi YM, "Ribavirin and interferon therapy for critically ill patients with Middle East Respiratory Syndrome : a multicenter observational study" 70 : 1837-1844, 2019

25 Omrani AS, "Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection : a retrospective cohort study" 14 : 1090-1095, 2014

26 Nyström K, "Ribavirin : pharmacology, multiple modes of action and possible future perspectives" 14 : 153-160, 2019

27 Soo YO, "Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients" 10 : 676-678, 2004

28 World Health Organization (WHO), "Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)"

29 Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial" 395 : 1569-1578, 2020

30 Hughes JP, "Principles of early drug discovery" 162 : 1239-1249, 2011

31 Dipiro JT, "Pharmacotherapy: a pathophysiologic approach" McGraw-Hill Education 2017

32 Sanders JM, "Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review" 2020

33 Ho JC, "Pentaglobin in steroid-resistant severe acute respiratory syndrome" 8 : 1173-1179, 2004

34 Magagnoli J, "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19" 2020

35 Shang L, "On the use of corticosteroids for 2019-nCoV pneumonia" 395 : 683-684, 2020

36 Tang X, "On the origin and continuing evolution of SARS-CoV-2" nwaa036-, 2020

37 Vastag B, "Old drugs for a new bug : influenza, HIV drugs enlisted to fight SARS" 290 : 1695-1696, 2003

38 Geleris J, "Observational study of hydroxychloroquine in hospitalized patients with Covid-19" 382 : 2411-2418, 2020

39 National Institutes of Health (NIH), "NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19"

40 Park JE, "MERS transmission and risk factors : a systematic review" 18 : 574-, 2018

41 Rygård SL, "Low-dose corticosteroids for adult patients with septic shock : a systematic review with meta-analysis and trial sequential analysis" 44 : 1003-1016, 2018

42 Yu B, "Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19" 15 : 1-7, 2020

43 Xiao K, "Isolation and characterization of 2019-nCoV-like coronavirus from Malayan Pangolins"

44 Leong HN, "Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003" 9 : 923-927, 2004

45 Kim Sun Bean, "Interim Guidelines on Antiviral Therapy for COVID-19" 대한감염학회 52 (52): 281-304, 2020

46 Lin FC, "Interferons : success in anti-viral immunotherapy" 25 : 369-376, 2014

47 Loutfy MR, "Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome : a preliminary study" 290 : 3222-3228, 2003

48 Lessler J, "Incubation periods of acute respiratory viral infections : a systematic review" 9 : 291-300, 2009

49 Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)" 71 : 732-739, 2020

50 Shalhoub S, "IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia : a retrospective study" 70 : 2129-2132, 2015

51 Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19 : results of an open-label non-randomized clinical trial" 56 : 105949-, 2020

52 Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding" 395 : 565-574, 2020

53 Holshue ML, "First case of 2019 novel coronavirus in the United States" 382 : 929-936, 2020

54 The COVID-19 investigation team, "First 12 patients with coronavirus disease 2019 (COVID-19) in the United States"

55 Chen C, "Favipiravir versus arbidol for COVID-19: a randomized clinical trial"

56 Yan D, "Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in patients with SARS-CoV-2 infection" 56 : 2000799-, 2020

57 Cai Q, "Experimental treatment with favipiravir for COVID-19: an open-label control study" 2020

58 Young BE, "Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore" 323 : 1488-1494, 2020

59 Chen Z, "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial"

60 Fritsch SD, "Effects of interferons and viruses on metabolism" 7 : 630-, 2016

61 Xu X, "Effective treatment of severe COVID-19 patients with tocilizumab" 117 : 10970-10975, 2020

62 Million M, "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin : A retrospective analysis of 1061 cases in Marseille, France" 35 : 101738-, 2020

63 Wu J, "Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease(COVID-19)" 288 : 128-138, 2020

64 Jiang X, "Does SARS-CoV-2 has a longer incubation period than SARS and MERS?" 92 : 476-478, 2020

65 Song P, "Cytokine storm induced by SARS-CoV-2" 509 : 280-287, 2020

66 Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation" 367 : 1260-1263, 2020

67 Baden LR, "Covid-19-The search for effective therapy" 382 : 1851-1852, 2020

68 Briel M, "Corticosteroids in patients hospitalized with community-acquired pneumonia : systematic review and individual patient data meta-analysis" 66 : 346-354, 2018

69 Stern A, "Corticosteroids for pneumonia" 12 : CD007720.-, 2017

70 Arabi YM, "Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome" 197 : 757-767, 2018

71 McCreary EK, "Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options" 7 : ofaa105-, 2020

72 Roback JD, "Convalescent plasma to treat COVID-19 : possibilities and challenges" 323 : 1561-1562, 2020

73 Peiris JS, "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study" 361 : 1767-1772, 2003

74 Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" 395 : 497-506, 2020

75 Chen CY, "Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome" 68 : 4-10, 2005

76 Russell CD, "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury" 395 : 473-475, 2020

77 Mahévas M, "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data" 369 : m1844-, 2020

78 Guan WJ, "Clinical Characteristics of Coronavirus Disease 2019 in China" 382 : 1708-1720, 2020

79 Guan WJ, "Clinical Characteristics of Coronavirus Disease 2019 in China" 382 : 1708-1720, 2020

80 Funck-Brentano C, "Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?" 2020

81 Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention" 2020

82 European Medicines Agency, "COVID-19: reminder of the risks of chloroquine and hydroxychloroquine"

83 National Institutes of Health (NIH), "COVID-19 treatment guidelines: Lopinavir/ritonavir and other HIV protease inhibitors"

84 Cai Q, "COVID-19 in a designated infectious diseases hospital outside Hubei Province, China" 75 : 1742-1752, 2020

85 Virlogeux V, "Brief report : Incubation period duration and severity of clinical disease following severe acute respiratory syndrome coronavirus infection" 26 : 666-669, 2015

86 Rosenberg ES, "Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State" 323 : 2493-2502, 2020

87 Virlogeux V, "Association between severity of MERS-CoV infection and incubation period" 22 : 526-528, 2016

88 Bessière F, "Assessment of QT intervals in a case series of patients with coronavirus disease 2019(COVID-19)infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit" e201787-, 2020

89 Zhu Z, "Arbidol monotherapy is superior to lopinavir/ ritonavir in treating COVID-19" 81 : e21-e23, 2020

90 Deng L, "Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019 : A retrospective cohort study" 81 : e1-e5, 2020

91 정용필, "Antiviral Treatment Guidelines for Middle East Respiratory Syndrome" 대한감염학회 47 (47): 212-222, 2015

92 Jeong SJ, "Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis" 17 : R97-, 2013

93 Elfiky AA, "Anti-HCV, nucleotide inhibitors, repurposing against COVID-19" 248 : 117477-, 2020

94 Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus" 426 : 450-454, 2003

95 Li Y, "An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)"

96 Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19" 382 : 1787-1799, 2020

97 Cortegiani A, "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19" 57 : 279-283, 2020

98 Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin" 579 : 270-273, 2020

99 Chen J, "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19" 49 : 215-219, 2020

100 Tsang KW, "A cluster of cases of severe acute respiratory syndrome in Hong Kong" 348 : 1977-1985, 2003